TScan Therapeutics, Inc.
TCRX
$1.60
-$0.12-6.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -127.50M | -111.30M | -104.41M | -96.80M | -89.22M |
| Total Depreciation and Amortization | 4.11M | 4.68M | 4.94M | 5.12M | 5.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.52M | 5.85M | 5.96M | 5.26M | 4.89M |
| Change in Net Operating Assets | 5.05M | -6.40M | 22.28M | 19.38M | 17.61M |
| Cash from Operations | -110.82M | -107.18M | -71.24M | -67.04M | -61.36M |
| Capital Expenditure | -3.83M | -3.41M | -3.46M | -3.01M | -3.15M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -48.79M | -74.59M | -53.60M | -20.75M | -57.61M |
| Cash from Investing | -52.61M | -77.99M | -57.05M | -23.76M | -60.76M |
| Total Debt Issued | 32.46M | -- | -- | -- | -- |
| Total Debt Repaid | -17.14M | -- | -- | -- | -- |
| Issuance of Common Stock | 35.18M | 34.82M | 33.59M | 43.56M | 43.30M |
| Repurchase of Common Stock | -- | -- | -176.00K | -176.00K | -176.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 158.27M | 128.27M | 128.20M | 92.32M | 92.32M |
| Cash from Financing | 208.77M | 163.09M | 161.61M | 135.70M | 135.44M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 45.33M | -22.08M | 33.32M | 44.91M | 13.33M |